drugset / Trial / NCT00647608

Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

NCT00647608

Phase 1 Completed 98 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's propranolol hydrochloride extended-release 160 mg capsules to Wyeth's Inderal® LA 160 mg capsules following a single, oral 160 mg (1 x 160 mg) dose administered under fed conditions.

Timeline

Start
2005-09
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 160 mg Oral

Indications

No indication recorded.